Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atomo DiagnosticsASX:AT1 Debt-to-Equity is 0.08 as of Dec. 2025, which is 700% above its 10-year median of 0.01. The stock has 4 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Atomo Diagnostics ranks better than 72.34% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Atomo Diagnostics's Debt-to-Equity or its related term are showing as below:
ASX:AT1'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.08
Current: 0.08
During the past 6 years, the highest Debt-to-Equity Ratio of Atomo Diagnostics was 0.08. The lowest was 0.00. And the median was 0.01.
ASX:AT1's Debt-to-Equity is ranked better than 72.34% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ASX:AT1: 0.08
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Atomo Diagnostics Debt-to-Equity Related Terms
Atomo Diagnostics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Atomo Diagnostics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AT1 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Atomo Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atomo Diagnostics (ASX:AT1) has a Debt-to-Equity of 0.08 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Atomo Diagnostics and its competitors. This is 700% above median its historical median of 0.01. According to the industry distribution chart, Atomo Diagnostics ranks #195 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 27.7%.
Is Atomo Diagnostics' Debt-to-Equity too high?
Atomo Diagnostics' current Debt-to-Equity of 0.08 is 700% above median its 10-year median of 0.01. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Atomo Diagnostics' value of 0.08 is 65.2% below this industry median. Based on the distribution chart, Atomo Diagnostics ranks #195 out of 705 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Atomo Diagnostics' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #195 out of 705 companies for Debt-to-Equity. This puts Atomo Diagnostics in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Atomo Diagnostics' value of 0.08 is 65.2% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.23, Atomo Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atomo Diagnostics's current Debt-to-Equity of 0.08 is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Atomo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current Debt-to-Equity is 0.08, which is 700% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Debt-to-Equity is 0.08, which is 700% above median its 10-year median of 0.01 and 65.2% below the Medical Devices & Instruments industry median of 0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Debt-to-Equity is 0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 
